Please login to the form below

Not currently logged in
Email:
Password:

fast track appraisal

This page shows the latest fast track appraisal news and features for those working in and with pharma, biotech and healthcare.

NICE’s fast-track catapults Skyrizi into market

NICE’s fast-track catapults Skyrizi into market

The drug is one of the first treatments to go through NICE’s fast-track appraisal system, which accelerates the review process and also cuts the standard 90 day implementation period ... This is even faster than J&J’s rival IL-23 inhibitor Tremfya,

Latest news

  • AbbVie’s Skyrizi gets rapid ‘yes’ from NICE AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

    New fast-track appraisal a boon for companies. AbbVie and Boehringer Ingelheim’s new psoriasis treatment Skyrizi has gained fast-track recommendation from NICE, coming less than three months after its ... AbbVie welcomed NICE’s decision, and said it

  • A first for Bluebird and Europe as gene therapy Zynteglo approved A first for Bluebird and Europe as gene therapy Zynteglo approved

    This was thanks to the EMA’s PRIME designation, a fast-track appraisal system particularly focused on cutting edge therapies from smaller-to-medium sized pharma and biotech firms.

  • NICE first fast-track appraisal backs Bayer's Eylea NICE first fast-track appraisal backs Bayer's Eylea

    The National Institute for Health and Care Excellence (NICE) has issued its first fast-track guidance, recommending Bayer’s Eylea (aflibercep) in choroidal neovascularisation (CNV). ... NICE’s fast track procedure is designed to give patients faster

  • NICE to create fast track for most cost-effective new drugs NICE to create fast track for most cost-effective new drugs

    Patients could get access to some medicines three months faster under a new 'fast track' appraisal process proposed by the UK's National Institute for Health and Care Excellence (NICE). ... Medicines qualifying for the fast-track process would have final

  • FDA will give BMS-Pfizer's Eliquis a priority review

    News that the FDA will fast-track its appraisal of the drug comes shortly after UK cost-effectiveness watchdog the National Institute for Health and Clinical Excellence (NICE) issued final draft ... This too was after a fast-tracked review process.

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics